Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Phase 3

Terminated

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Copanlisib (BAY80-6946)
Drug: Placebo
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Bendamustine
Drug: Prednisone

First Posted Date: 2015-12-10

Last Posted Date: 2024-12-11

Lead Sponsor: Bayer

Target Recruit Count: 551

Registration Number: NCT02626455

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center- Bergen, New York, New York, United States
🇧🇷
Hospital de Clinicas de Porto Alegre | Clinical Research Center - Surgery Research Center, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷
Irmandade da Santa Casa de Misericordia de Porto Alegre | Hospital Sao Francisco - Centro Medico Pesquisa Clinica Cardiologia, Porto Alegre, Rio Grande Do Sul, Brazil

and more 198 locations

MabionCD20 Compared to MabThera in Lymphoma Patients

Phase 3

Completed

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide
Drug: prednisone

First Posted Date: 2015-12-01

Last Posted Date: 2023-10-25

Lead Sponsor: Mabion SA

Target Recruit Count: 143

Registration Number: NCT02617485

Locations: 🇬🇪
Medulla - Chemotherapy and Immunotherapy Clinic, Tbilisi, Georgia
🇭🇷
GH "dr.Josip Bencevic", Slavonski Brod, Croatia
🇭🇷
CHC Zagreb, Zagreb, Croatia

and more 32 locations

Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Phase 2

Withdrawn

Conditions: Lymphoma

Interventions: Drug: Duvelisib
Drug: Rituximab
Drug: R-CHOP
Drug: Prednisone

First Posted Date: 2015-11-16

Last Posted Date: 2021-03-17

Lead Sponsor: SecuraBio

Registration Number: NCT02605694

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1

Completed

Conditions: Diffuse Large B-Cell Lymphoma, Lymphoma Follicular

Interventions: Drug: Atezolizumab
Drug: Bendamustine
Drug: Cyclophosphamide
Drug: Obinutuzumab
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine
Drug: Rituximab

First Posted Date: 2015-11-04

Last Posted Date: 2021-05-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 91

Registration Number: NCT02596971

Locations: 🇦🇺
Concord Repatriation General Hospital; Haematology, Sydney, New South Wales, Australia
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Oncology Associates of Oregon, P.C.; Willamette Valley Cancer Institute, Springfield, Oregon, United States

and more 18 locations

Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma

Phase 1

Withdrawn

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2015-11-03

Last Posted Date: 2017-05-23

Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Registration Number: NCT02595242

Locations: 🇨🇳
Tianjin people's Hospital, Tianjin, China

Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo matched to prednisone
Drug: Prednisone
Biological: Tocilizumab

First Posted Date: 2015-10-09

Last Posted Date: 2019-11-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 314

Registration Number: NCT02573012

Locations: 🇫🇷
Hopital Pellegrin; Rhumatologie, Bordeaux, France
🇫🇷
Hopital Cochin; Rhumatologie B, Paris, France
🇫🇷
Hopital Hautepierre; Rhumatologie, Strasbourg, France

and more 36 locations

Glucocorticoids With Antihistamines Versus Antihistamines in Acute Urticaria in Emergency

Phase 2

Completed

Conditions: Acute Urticaria

Interventions: Drug: placebo
Drug: prednisone

First Posted Date: 2015-10-01

Last Posted Date: 2023-05-23

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 100

Registration Number: NCT02565680

Locations: 🇫🇷
CHU Toulouse, Toulouse, France

The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery

Not Applicable

Completed

Conditions: Chronic Sinusitis
Nasal Polyposis

Interventions: Device: MEDIHONEY®
Drug: Budesonide
Drug: Normal saline sinus rinse
Drug: Prednisone
Procedure: Endoscopic sinus surgery
Drug: nasal saline spray

First Posted Date: 2015-09-29

Last Posted Date: 2019-10-16

Lead Sponsor: University of Vermont Medical Center

Target Recruit Count: 40

Registration Number: NCT02562924

Locations: 🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive
Anaplastic Large Cell Lymphoma, ALK-Negative
Stage II Angioimmunoblastic T-cell Lymphoma
Stage IV Enteropathy-Associated T-Cell Lymphoma
Stage III Angioimmunoblastic T-cell Lymphoma
Stage IV Angioimmunoblastic T-cell Lymphoma
Stage II Enteropathy-Associated T-Cell Lymphoma
Hepatosplenic T-Cell Lymphoma
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Stage III Enteropathy-Associated T-Cell Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Prednisone
Drug: Vincristine Sulfate

First Posted Date: 2015-09-28

Last Posted Date: 2023-12-13

Lead Sponsor: University of Nebraska

Target Recruit Count: 54

Registration Number: NCT02561273

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸
University of Colorado Cancer Center, Anschutz Cancer Pavilion, Aurora, Colorado, United States

and more 5 locations

Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis

Phase 2

Terminated

Conditions: Cryoglobulinemia
Systemic Vasculitis

Interventions: Drug: rituximab
Drug: Prednisone
Drug: Placebo

First Posted Date: 2015-09-22

Last Posted Date: 2019-03-18

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 14

Registration Number: NCT02556866

Locations: 🇫🇷
Pitié Salpetriere Hospital, Paris, France

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy